

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Brilliant Violet 605(TM) anti-mouse/human CD11b

RRID:AB_2565431

Type: Antibody

Proper Citation

BioLegend Cat# 101257, RRID:AB_2565431

Antibody Information

URL: http://antibodyregistry.org/AB_2565431

Proper Citation: BioLegend Cat# 101257, RRID:AB_2565431

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_2565431

Vendor: BioLegend

Catalog Number: 101257

Alternative Catalog Numbers: 101237

Record Creation Time: 20250820T055416+0000

Record Last Update: 20250820T224617+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse/human CD11b.

No alerts have been found for Brilliant Violet 605(TM) anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 77 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Diamond EL, et al. (2026) RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. *Cancer cell*, 44(1), 203.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. *Cancer immunology research*, 14(5), 718.

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. *iScience*, 29(6), 115978.

Skytthe M, et al. (2026) CD163 Expression Protects Against Early Hepatic Steatosis in Western Diet-Fed Male Mice. *Gastro hep advances*, 5(1), 100809.

Voisin T, et al. (2026) Skin inflammation and itch response are independently regulated by distinct nociceptor subsets. *Immunity*, 59(5), 1237.

Bolli E, et al. (2026) CCL3 is produced by aged neutrophils across cancers and promotes tumor growth. *Cancer cell*, 44(3), 624.

Xu S, et al. (2026) Engineered MSCs enable bone marrow-targeted immunomodulation. *Cell stem cell*, 33(4), 660.

Tang M, et al. (2026) TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. *Cell reports. Medicine*, 7(7), 102876.

Kim JS, et al. (2025) Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging mice. *Cell reports*, 44(5), 115609.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. *Immunity*, 58(7), 1670.

Mirji G, et al. (2025) Aromatic microbial metabolite hippuric acid enhances inflammatory responses in macrophages via TLR-MyD88 signaling and lipid remodeling. *Cell reports*, 45(1), 116749.

Lamorte S, et al. (2025) Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. *Cancer cell*, 43(5), 955.

Lanzar ZR, et al. (2025) De-coupling immune parameters and toxicity associated with IL-12 agonism. *Cell reports*, 44(6), 115840.

Lucotti S, et al. (2025) Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. *Cell*, 188(6), 1642.

Keating N, et al. (2025) ARAP2 regulates responses to interferon-gamma by restricting SOCS1. *Cell reports*, 44(12), 116667.

Tursi NJ, et al. (2025) Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity. *Cell reports. Medicine*, 6(4), 102035.

Mayerhofer C, et al. (2025) OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis. *Cell metabolism*.

Reyes EY, et al. (2025) *Cryptococcus* exploits delayed microglial activation, and microglial osteopontin/Spp1 impairs peripheral host control. *Cell host & microbe*, 33(12), 2067.

Wienke J, et al. (2024) Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. *Cancer cell*, 42(2), 283.

Jia D, et al. (2024) Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. *Cell*, 187(7), 1651.